Parathyroid Hormone-Related Protein 1-36
Also known as: hPTHrP(1-36), Parathyroid hormone-related peptide (1-36), Parathyroid hormone‑related protein 1‑36, PTHrP (1-36), PTHrP 1-36, PTHrP(1-36)
Source Parathyroid Hormone-Related Protein 1-36 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
A 36‑amino‑acid fragment of PTHrP that mimics the N‑terminal activity of the full‑length hormone; used experimentally to study bone remodeling and calcium homeostasis.
Mechanism of Action
Agonist of the PTH1 receptor, stimulating cAMP production and calcium mobilization
Routes of Administration
Goals & Uses
- Osteoporosis treatmentBone MetabolismModerate
- Anabolic bone therapyMusculoskeletalModerate
- Research tool for PTH1R signalingResearchHigh
- HypoparathyroidismCalcium DeficiencyLow
- Hypercalcemia of malignancy researchOncology / Calcium MetabolismLow
- Reduction of fracture riskOsteoporosisLow
- Increase bone mineral densityBone HealthModerate
Contraindications
- Active malignancy with bone metastasesOncologyModerate
- HypercalcemiaMetabolic DisorderHigh
- Severe renal impairmentOrganModerateKidney function concerns
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Paget's disease of boneBone DisorderModerate
- History of skeletal malignancy or bone metastasesOncologyHigh
- Severe hypercalcemiaElectrolyte DisorderHigh
Adverse Effects
- Elevated bone turnover markersLaboratoryCommon
- Hypercalcemia / hypercalciuriaMetabolicCommon
- HypercalcemiaMetabolicCommon
- Injection site reactionsLocalCommon
- Injection site painLocalCommonPain at the injection site
- HypotensionCardiovascularUncommonLow blood pressure
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Dizziness / orthostatic hypotensionCardiovascularUncommon
Drug Interactions
- Loop diureticsModerate
- BisphosphonatesLow
- DigoxinHigh
- Calcium and Vitamin D supplementsLow
- Thiazide diureticsModerate
Population Constraints
- Pediatric patientsAgeRelative
- ElderlyAgeRelative
- Elderly patients (>75 years)AgeRelative
- Pregnant womenReproductiveRelative
- Patients with nephrolithiasis historyRenalRelative
- ChildrenPediatricRelative
Regulatory Status
- European UnionInvestigationalUnder clinical evaluation; not authorized.
- United StatesInvestigationalInvestigational New Drug (IND) application filed; not FDA‑approved.
- United KingdomInvestigationalNo MHRA approval; research compound
Not approved for clinical use; investigated in early‑phase trials for osteoporosis and hypoparathyroidism.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Parathyroid Hormone-Related Protein 1-36?
A 36‑amino‑acid fragment of PTHrP that mimics the N‑terminal activity of the full‑length hormone; used experimentally to study bone remodeling and calcium homeostasis.
What is Parathyroid Hormone-Related Protein 1-36 used for?
Parathyroid Hormone-Related Protein 1-36 is educationally associated with: Osteoporosis treatment, Anabolic bone therapy, Research tool for PTH1R signaling, Hypoparathyroidism, Hypercalcemia of malignancy research, Reduction of fracture risk, Increase bone mineral density. Educational only — not medical advice.
How is Parathyroid Hormone-Related Protein 1-36 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Parathyroid Hormone-Related Protein 1-36?
Reported adverse effects include: Elevated bone turnover markers, Hypercalcemia / hypercalciuria, Hypercalcemia, Injection site reactions, Injection site pain, Hypotension, Nausea, Dizziness / orthostatic hypotension. This list is not exhaustive — consult a qualified clinician.
Who should avoid Parathyroid Hormone-Related Protein 1-36?
Recorded contraindications: Active malignancy with bone metastases, Hypercalcemia, Severe renal impairment, Pregnancy, Paget's disease of bone, History of skeletal malignancy or bone metastases, Severe hypercalcemia. Consult a qualified clinician before use.